KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Other Operating Expenses (2017 - 2023)

BeOne Medicines (ONC) has disclosed Other Operating Expenses for 7 consecutive years, with $1.5 billion as the latest value for Q4 2023.

  • On a quarterly basis, Other Operating Expenses rose 83.63% to $1.5 billion in Q4 2023 year-over-year; TTM through Sep 2024 was $1.5 billion, a 83.54% increase, with the full-year FY2023 number at $1.5 billion, up 44.72% from a year prior.
  • Other Operating Expenses was $1.5 billion for Q4 2023 at BeOne Medicines, up from $188000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $1.5 billion in Q4 2023 to a low of -$116.9 million in Q4 2021.
  • A 5-year average of $136.7 million and a median of $21.3 million in 2020 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: crashed 649.82% in 2021, then skyrocketed 775.52% in 2022.
  • BeOne Medicines' Other Operating Expenses stood at $18.3 million in 2019, then increased by 16.11% to $21.3 million in 2020, then plummeted by 649.82% to -$116.9 million in 2021, then surged by 775.52% to $789.8 million in 2022, then soared by 83.63% to $1.5 billion in 2023.
  • Per Business Quant, the three most recent readings for ONC's Other Operating Expenses are $1.5 billion (Q4 2023), $188000.0 (Q2 2023), and $187000.0 (Q1 2023).